Current Opinion in Nephrology and Hypertension

Potential kidney toxicity from the antiviral drug tenofovir: New indications, new formulations, and a new prodrug.  27:102-112. 2018

Refractory versus resistant hypertension.  26:14-19. 2017

The role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.  25:314-324. 2016

Endothelin-1 and the kidney: New perspectives and recent findings.  25:35-41. 2016

Dialysate content and risk of sudden cardiac death.  24:557-562. 2015

Pathophysiology of the chronic kidney disease - Mineral bone disorder.  24:303-309. 2015

Current status on the evaluation and management of the highly sensitized kidney transplant recipient.  24:570-575. 2015

Medical management of chronic kidney disease in the renal transplant recipient.  24:587-593. 2015

Pathogenesis of immunoglobulin A nephropathy.  22:287-294. 2013

Nitric oxide and the A and B of endothelin of sodium homeostasis.  22:26-31. 2013

Fibroblast growth factor 23 and the heart.  21:369-375. 2012

Increased serum phosphate and adverse clinical outcomes: Unraveling mechanisms of disease.  20:224-228. 2011

Mechanisms and consequences of salt sensitivity and dietary salt intake.  20:37-43. 2011

Uric acid: A novel mediator and marker of risk in chronic kidney disease?.  18:526-530. 2009

Tubuloglomerular feedback mechanisms in nephron segments beyond the macula densa.  18:57-62. 2009

Renin inhibition: Should it supplant ACE inhibitors and ARBS in high risk patients?.  17:484-490. 2008

Endothelin and NOS1/nitric oxide signaling and regulation of sodium homeostasis.  17:70-75. 2008

Vascular stenosis: Biology and interventions.  16:516-522. 2007

Effect of salt intake on progression of chronic kidney disease.  15:54-60. 2006

Hormonal and cytokine effects of uric acid.  15:30-33. 2006

Fabry disease: Diagnosis and management, with emphasis on the renal manifestations.  14:87-95. 2005

Management of paraproteinemic renal disease.  14:97-103. 2005

IgA nephropathy: An update.  13:171-179. 2004

A family of calcium-permeable channels in the kidney: Distinct roles in renal calcium handling.  11:555-561. 2002

Hormone replacement therapy and hypertension.  11:229-235. 2002

Genetic forms of human hypertension.  10:493-499. 2001

Interaction of syntaxins with epithelial ion channels.  9:523-527. 2000

Renal endothelin in hypertension.  9:157-164. 2000

Sodium transporters in health and disease.  6:372-376. 1997

Antihypertensive therapy in the era of evidence based medical practice: What to do until the facts are in.  5:159-161. 1996

Hypertension in postmenopausal women: Pathophysiology and management.  4:438-442. 1995

Hypertension in women.  4:204-207. 1995

Antihypertensive therapy in the context of total cardiovascular risk: the rational basis for therapeutic recommendations..  3:195-199. 1994

Neurologic consequences of hypertension and antihypertensive drug therapy..  3:228-235. 1994

Renal involvement in plasma cell dyscrasias..  2:246-252. 1993

The role of the sympathetic nervous system in hypertension..  2:265-273. 1993